Altimmune (ALT) News Today $6.89 +0.02 (+0.29%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$6.84 -0.04 (-0.65%) As of 06/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Altimmune (NASDAQ:ALT) Rating Lowered to "Sell" at Wall Street ZenJune 15 at 3:05 AM | americanbankingnews.comAltimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street ZenWall Street Zen lowered shares of Altimmune from a "hold" rating to a "sell" rating in a research note on Saturday.June 14, 2025 | marketbeat.comAltimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific SessionsJune 13, 2025 | finance.yahoo.comAltimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific SessionsJune 13, 2025 | globenewswire.comAltimmune (NASDAQ:ALT) Trading 8.7% Higher - Still a Buy?Altimmune (NASDAQ:ALT) Trading 8.7% Higher - What's Next?June 10, 2025 | marketbeat.comSquarepoint Ops LLC Cuts Stock Position in Altimmune, Inc. (NASDAQ:ALT)Squarepoint Ops LLC lessened its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 76.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 14,706 shares of the company's stock after selling 46,982 shares during the period. SquarepointJune 10, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Receives $20.20 Consensus PT from BrokeragesJune 9, 2025 | americanbankingnews.comAltimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Buy" by BrokeragesShares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus rating of "Buy" from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendatioJune 6, 2025 | marketbeat.comFY2026 Earnings Forecast for Altimmune Issued By B. RileyAltimmune, Inc. (NASDAQ:ALT - Free Report) - Equities research analysts at B. Riley issued their FY2026 earnings estimates for Altimmune in a note issued to investors on Monday, June 2nd. B. Riley analyst M. Mamtani anticipates that the company will post earnings of $0.19 per share for the year.June 5, 2025 | marketbeat.comRFG Advisory LLC Makes New Investment in Altimmune, Inc. (NASDAQ:ALT)RFG Advisory LLC purchased a new position in Altimmune, Inc. (NASDAQ:ALT - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 324,397 shares of the company's stock, valued at approximateJune 5, 2025 | marketbeat.comAltimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover PotentialJune 2, 2025 | seekingalpha.comAltimmune, Inc. (NASDAQ:ALT) Stock Holdings Increased by Millennium Management LLCMillennium Management LLC lifted its position in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 139.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 345,637 shares of the company's stock after buying an additional 201,484 shares duJune 1, 2025 | marketbeat.comTwo Sigma Investments LP Raises Holdings in Altimmune, Inc. (NASDAQ:ALT)Two Sigma Investments LP boosted its holdings in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 33.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 605,303 shares of the company's stock afteMay 30, 2025 | marketbeat.comFY2029 EPS Estimate for Altimmune Decreased by AnalystAltimmune, Inc. (NASDAQ:ALT - Free Report) - HC Wainwright dropped their FY2029 earnings estimates for shares of Altimmune in a report released on Thursday, May 22nd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $1.22 for the year, down from theirMay 27, 2025 | marketbeat.comAltimmune (NASDAQ:ALT) Upgraded to Hold at StockNews.comStockNews.com raised Altimmune from a "sell" rating to a "hold" rating in a research note on Thursday.May 24, 2025 | marketbeat.com13 Best Multibagger Stocks to Invest in NowMay 21, 2025 | insidermonkey.comCould Altimmune, Inc. (ALT): Analysts See 288% Upside PotentialMay 21, 2025 | insidermonkey.comFocus Partners Wealth Invests $884,000 in Altimmune, Inc. (NASDAQ:ALT)Focus Partners Wealth bought a new stake in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 122,539 shares of the company's stock, valued at approximatelyMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $3.32 Million Holdings in Altimmune, Inc. (NASDAQ:ALT)D. E. Shaw & Co. Inc. reduced its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 39.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 459,833 shares of the company's stock after selling 298,May 21, 2025 | marketbeat.comHC Wainwright Has Strong Forecast for Altimmune Q2 EarningsAltimmune, Inc. (NASDAQ:ALT - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2025 earnings estimates for Altimmune in a research report issued on Thursday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.33) per share for thMay 20, 2025 | marketbeat.comAltimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)May 19, 2025 | globenewswire.comBaird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT)Baird Financial Group Inc. bought a new stake in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 59,440 shares of the company's stock, valued at aMay 18, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Stock Holdings Raised by Ensign Peak Advisors IncEnsign Peak Advisors Inc raised its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 39.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 454,981 shares of the company's stock after purchasing an additional 128,204 shares during the period. Ensign Peak AdMay 17, 2025 | marketbeat.comEvercore ISI Sticks to Its Buy Rating for Altimmune (ALT)May 17, 2025 | theglobeandmail.comEarnings call transcript: Altimmune Q1 2025 results show narrower lossMay 15, 2025 | uk.investing.comAltimmune, Inc. (NASDAQ:ALT) Shares Purchased by Ameriprise Financial Inc.Ameriprise Financial Inc. boosted its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 35.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,254,898 shares of the company's stock after buying an additional 1,378,854 shMay 15, 2025 | marketbeat.comAltimmune to Participate at Two Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comAltimmune (ALT) Receives a Buy from Stifel NicolausMay 14, 2025 | theglobeandmail.comAltimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runwayMay 14, 2025 | msn.comQ1 2025 Altimmune Inc Earnings CallMay 14, 2025 | finance.yahoo.comAltimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic DevelopmentsMay 14, 2025 | finance.yahoo.comAltimmune, Inc. (ALT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comAltimmune, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 13, 2025 | seekingalpha.comAltimmune Secures Up to $100 Million in Credit Facility from Hercules CapitalMay 13, 2025 | globenewswire.comAltimmune Announces First Quarter 2025 Financial Results and Business UpdateMay 13, 2025 | globenewswire.comAltimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Buy" by AnalystsAltimmune, Inc. (NASDAQ:ALT - Get Free Report) has received an average rating of "Buy" from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a stroMay 13, 2025 | marketbeat.com3ALT : What to Expect from Altimmune's EarningsMay 12, 2025 | benzinga.comAltimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™May 8, 2025 | globenewswire.comAltimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025May 6, 2025 | globenewswire.comBellevue Group AG Acquires 81,786 Shares of Altimmune, Inc. (NASDAQ:ALT)Bellevue Group AG grew its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 9.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 945,446 shares of the company's stock after acquiring an additional 81,786 shareMay 6, 2025 | marketbeat.comMarshall Wace LLP Makes New $472,000 Investment in Altimmune, Inc. (NASDAQ:ALT)Marshall Wace LLP acquired a new stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 65,517 shares of the company's stock, valued at approximately $472,000. Marshall Wace LLP owned 0.09% of AltimMay 5, 2025 | marketbeat.comAltimmune (ALT) Projected to Post Quarterly Earnings on ThursdayAltimmune (NASDAQ:ALT) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-altimmune-inc-stock/)May 3, 2025 | marketbeat.comInvesco Ltd. Acquires 215,375 Shares of Altimmune, Inc. (NASDAQ:ALT)Invesco Ltd. increased its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 679.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 247,086 shares of the company's stock after purchasing an additional 21May 2, 2025 | marketbeat.comWill Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?May 1, 2025 | finance.yahoo.comAltimmune to Present at Upcoming EASL International Liver Congress™ 2025May 1, 2025 | globenewswire.comAltimmune to Participate in the Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comWells Fargo & Company MN Purchases 88,209 Shares of Altimmune, Inc. (NASDAQ:ALT)Wells Fargo & Company MN increased its position in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 69.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 215,538 shares of the company's stock after acquiring an additional 88April 29, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Moderate Buy" from AnalystsShares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have issuedApril 18, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. lessened its holdings in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 11.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,431,612 shares of the company's stock after selling 552,246 shares dApril 15, 2025 | marketbeat.comAltimmune's US$42m Market Cap Fall Books Insider LossesApril 10, 2025 | uk.finance.yahoo.com Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address ALT Media Mentions By Week ALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.620.90▲Average Medical News Sentiment ALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼46▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NewAmsterdam Pharma News Bausch Health Companies News Arrowhead Pharmaceuticals News Denali Therapeutics News Twist Bioscience News Vericel News Kiniksa Pharmaceuticals News Agios Pharmaceuticals News Sarepta Therapeutics News Recursion Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhat 99% of investors are missing about Chinese AIChinese AI chatbot DeepSeek's release put the spotlight on AI and turned the tech world on its head. But 99...Weiss Ratings | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALT Stock Free ALT Stock Alerts